PLIN2 and metabolic dysfunction-associated steatotic liver disease: Given that PLIN2 is expressed in various non-adipose tissues, the potential contribution of subclinical extra-hepatic comorbidities to systemic levels cannot be entirely excluded, highlighting the need for further investigation into the pathophysiological specificity of PLIN2 within the heterogeneous NAFLD spectrum.